Osborne W, Haynes E, Wilson W, Ediriwickrema K, Paterson J, Menne T, El-Sharkawi D, Chan LY, Iyengar S, Davies AJ, Hiew HJ, Kanfer E, Foldes D, Chaganti S, Crosland H, Owen M, Follows G, Santarsieri A, Lawless S, Wilson M, McKay P, Osborn R, Tucker D, Thiebaud CM, Fox CP, Ambrose H, Gleeson M, Lam J, Broom A, Smith J, Wells M, Oldham L, Linton K, Jeffers L, Kuhnl A, Collins G, Qasim J, Shah N, McCulloch R, Baloch M, Cox C, Lewis D, Martin A, Maw KZD, Norman J, Deshani V, Stables V, Preston G, Culligan D, Willan J, Ahearne M, Motiwale R, Dunning L, Fawcett J, Kelsey P, Besley C, Lugthart S, Easton J, Gurung S, Ojie D, Mathew S, Auer R, Townsend W. Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing. haematol [Internet]. 2020Sep.10 [cited 2026May14];. Available from: https://haematologica.org/article/view/14177